Acute kidney injury in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody vs. immune checkpoint inhibitors: a retrospective real-world study

Jianfen Zhu,Xiaokai Ding,Jianna Zhang,Bo Chen,Xiaohan You,Xinxin Chen,Tianxin Chen
DOI: https://doi.org/10.1186/s12885-024-12540-y
IF: 4.638
2024-06-25
BMC Cancer
Abstract:Anti-vascular endothelial growth factor monoclonal antibody (anti-VEGF) or immune checkpoint inhibitors (ICIs) combined with chemotherapy are commonly administered to cancer patients. Although cancer patients receiving anti-VEGF or ICIs have been reported to experience an increased risk of acute kidney injury (AKI), comparative studies on the AKI incidence have not been evaluated.
oncology
What problem does this paper attempt to address?